No profile data available.
Greenwich LifeSciences, Inc. (GLSI) is a healthcare company in the breast cancer treatment drugs industry, based in Stafford, United States.
It reported revenue of $0 for fiscal year 2024, and net income of -$15.79 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $242.63 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Greenwich LifeSciences reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$242.63 million as of October 9, 2026.
Listed companies of a similar size in the same industry (breast cancer treatment drugs) include Celcuity Inc. (CELC), Olema Pharmaceuticals, Inc. (OLMA), Puma Biotechnology, Inc. (PBYI), Odonate, Inc. (ODTC).